Superior vena cava (SVC) syndrome is often associated with central venous catheters, hemodialysis catheters, or pacemaker electrodes. Endovascular recanalization procedures are a mainstay therapy to enable quick relief from symptoms in these vascular emergencies. Venoplasty with stenting is often necessary to ensure a good long-term result. In situ catheters reaching into the SVC might be jailed by stent placement between the stent and the vessel wall in the process and hence could be compromised in their function.

We report a case in which we chose to perform a temporary snaring procedure of a port-a-cath tube in the setting of SVC syndrome to avoid catheter removal and later reinsertion with the associated risks and to minimize health care-related cost. The patient consented to publication of this report.

Case report {#sec1}
===========

A 55-year-old woman (155 cm, 55 kg) who had undergone hemicolectomy because of an obstructing adenocarcinoma of the ascending colon 6 months ago presented in the emergency department because of a progressive swelling of her face and neck and arms, cyanosis and edema of both hands, and shortness of breath at rest for the last 12 days. Until 20 days ago, she had been receiving subsequent adjuvant chemotherapy with FOLFOX, which was administered through a port-a-cath. In addition to the presenting symptoms, the physical examination showed dilated jugular veins in the upright position. There were no local signs of infection in the area of the implanted port-a-cath and no edema of the lower extremities. Her medical history further showed a substituted hypothyroidism after thyroidectomy for struma nodosa. Initial diagnostic workup contained a computed tomography scan, which showed thrombosis of the SVC reaching from the caval confluence of the azygos vein to both brachiocephalic veins into the left subclavian vein ([Fig 1](#fig1){ref-type="fig"}). Vascular compression by a tumor or lymphadenopathy and pulmonary embolism were ruled out. Echocardiography showed normal systolic and diastolic function of the heart, no valvulopathies, and normal-sized left and right ventricles. No intracardiac clots were detected. Laboratory analysis showed normal red and white blood cell counts. The international normalized ratio was 0.91. All electrolytes, C-reactive protein, thyroid-stimulating hormone, and kidney function parameters were within normal range.Fig 1Computed tomography scan **(A)** and phlebography **(B)** of thrombosis of the superior vena cava (SVC) and both brachiocephalic veins (*arrow*).

Therapeutic procedure and assessment {#sec1.1}
------------------------------------

Because of the newly diagnosed thrombosis, the patient was treated with a therapeutic dose of unfractionated heparin (Liquemin; Drossapharm, Basel, Switzerland) and transferred to our hospital for endovascular revascularization.

We performed venography over the right basilic vein and confirmed the diagnosis of an occlusion of the SVC. We opted for a catheter-based thrombectomy (AngioJet 8F ZelanteDVT; Boston Scientific, Marlborough, Mass) with PowerPulse spray delivery of 10 mg of alteplase (Actilyse; Boehringer Ingelheim, Basel, Switzerland) into the thrombus.[@bib1], [@bib2] Removal of fresh thrombotic material revealed extended post-thrombotic changes in the proximal brachiocephalic vein and the SVC. To completely unmask the extent of post-thrombotic changes, we placed a valved-tip, multiple-side hole lysis catheter (Cragg-McNamara; ev3 Neurovascular, Irvine, Calif) for local thrombolysis during 15 hours (2 mg/h for 5 hours, 1 mg/h for 10 hours). Second-look phlebography the next day further showed a high-grade (75%), chronic, post-thrombotic stenosis of the SVC, which was associated with the tip position of the port-a-cath that had been placed through the left subclavian vein ([Fig 2](#fig2){ref-type="fig"}). To ensure unrestrained venous inflow and to prevent secondary SVC syndrome, we decided to perform percutaneous transluminal angioplasty and stenting of the lesion. However, to prevent jailing of the port-a-cath tube by stent placement to keep it functional in case of future chemotherapy and to avoid surgical removal and the need for reimplantation with subsequent risk of thrombosis progression during perioperative pausing of anticoagulation, endovascular repositioning of the port-a-cath tube before percutaneous transluminal angioplasty and stenting was considered in a first approach. Over an 8F sheath access in the right basilic vein, the stenosis was passed using a 0.035-inch guidewire (Radiofocus Guidewire M, stiff type; Terumo, Tokyo, Japan) and a Navicross support catheter (Terumo). Afterward, a snare (Atrieve Vascular Snare Kit 18-30 mm; Argon Medical Devices, Plano, Tex) was inserted over a delivery catheter, and the tip of the port-a-cath was captured in the SVC and pulled back into the right brachiocephalic vein ([Fig 3](#fig3){ref-type="fig"}). Then, balloon angioplasty (Atlas Gold 12/40 mm; Bard Peripheral Vascular, Tempe, Ariz), stent implantation (sinus-XL, 18/60 mm; OptiMed, Ettlingen, Germany), and postdilation (Atlas Gold 14/40 mm) were performed over a 10F sheath (Avanti sheath introducer; Cordis, Miami Lakes, Fla) access in the right common femoral vein. After successful stent implantation, the catheter was snared from the right common femoral vein and pulled back into the stent ([Fig 4](#fig4){ref-type="fig"}). Venography at the end of the examination showed an unrestricted venous inflow ([Fig 5](#fig5){ref-type="fig"}).Fig 2High-grade chronic, post-thrombotic stenosis of the superior vena cava (SVC) at the tip position of the port-a-cath after AngioJet thrombectomy (*arrow*).Fig 3**A** and **B,** Snaring of the port-a-cath tube from the superior vena cava (SVC) into the right brachiocephalic vein using an Atrieve Vascular Snare Kit 18-30 mm (Argon Medical Devices, Plano, Tex).Fig 4**A** and **B,** Snaring of the catheter from the right common femoral vein back into the stent using an Atrieve Vascular Snare Kit 18-30 mm.Fig 5Venous inflow after restoration of the superior vena cava (SVC) with port-a-cath in place.

An oral anticoagulation regimen with rivaroxaban 15 mg twice daily was initiated for 3 weeks, followed by 20 mg every day.

The follow-up visit after 3 months showed no clinical signs of a stent occlusion. Duplex ultrasound confirmed normal venous inflow. The port-a-cath was still in situ with regular function. A decision was made to continue the anticoagulation regimen with rivaroxaban until port-a-cath explantation.

Discussion {#sec2}
==========

An SVC syndrome caused by a lumen-obstructing thrombosis is often associated with central venous catheters or pacemaker electrodes. The growing use of these central venous devices is reflected in increasing cases of thrombosis of the vena cava,[@bib3], [@bib4], [@bib5] which occurs in 0.2% to 3.3% of these patients. Prothrombotic conditions (eg, cancer, chemotherapy, thrombophilia, and external compression) increase the risk of thrombosis.[@bib6] In patients with an underlying malignant disease, the incidence of thrombosis associated with the use of central venous catheters is estimated to be up to 30%.[@bib1], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11] A feared complication is progression of thrombosis into the SVC. The symptoms caused by a vena cava thrombosis depend on the time of thrombus progression to flow-limiting obstruction and the capacity of collateral vein drainage through the azygos vein, internal mammary veins, lateral thoracic vein, and paraspinal and esophageal veins.[@bib2], [@bib12]

If there is an acute occlusion of the SVC, the most common symptoms are swelling of the face and neck and arms, cyanosis, venous stasis on the shoulders and neck, orthopnea, and dyspnea. Headaches, dizziness, syncope, confusion, and somnolence (caused by increasing intracranial pressure) as well as pulmonary embolism and hemodynamic instability can quickly lead to life-threatening situations that are associated with unfavorable outcomes.[@bib2]

In the past, SVC syndrome not associated with cancer has been treated conservatively with anticoagulants, diuretics, and corticosteroids, keeping the patient in an upright position with head elevation. A surgical treatment option is a median sternotomy with venous bypass graft.[@bib13] In past years, endovascular recanalization procedures have evolved as a mainstay of invasive therapy to enable quick relief from symptoms in these vascular emergencies.[@bib1] Catheter-based therapy and thrombolysis must be considered in acute onset of SVC syndrome (symptoms \<14 days, progressive symptoms, life-threatening situations).[@bib2], [@bib8] Computed tomography angiography is recommended to exclude the most common causes (tumors, lymphoma, struma) of SVC syndrome, to exclude pulmonary embolism, and to evaluate proximal thrombosis extension. For anatomic reasons, venoplasty with stenting is necessary when there is a relevant chronic stenosis (usually due to fibrosis or tumor mass) left after the thrombus burden is dissolved because of better patency rates after stenting in those cases than with angioplasty alone. The technical success rate of stenting of the SVC or its branches is 95% to 100%, with a 2-year primary patency rate up to 76% and secondary patency rates up to 95%.[@bib14] Acute complications of stent placement for SVC syndrome have been reported in 3% to 7% of patients, including infection, pulmonary embolism, stent migration, hematoma at the insertion site, supraventricular arrhythmia, bleeding, and perforation (rarely).

Because pulmonary embolism as a complication of SVC stenting is rare and placement of an SVC filter bears the risk of severe complications, SVC filter placement to prevent pulmonary embolism should be performed only in special situations.[@bib1] In situ catheters (eg, port-a-cath, hemodialysis catheters) pose the problem that they would be jailed by stent placement between the stent and the vessel wall and hence would be compromised in their function.[@bib15]

Conclusions {#sec3}
===========

To avoid catheter removal and reinsertion with the associated risks (bleeding, pneumothorax, rethrombosis, thrombosis progression, pulmonary embolism, infection) and to minimize health care-related cost, single-session temporary snaring of the catheter with endovascular replacement is a feasible treatment option after thrombectomy and therapy for the SVC syndrome.[@bib7]
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